Recombinant Proteins Market Analysis

Application (Research, Therapeutics, Healthcare)

The global recombinant proteins market is segmented and analyzed for demand and supply by application into research, therapeutics, and healthcare. Out of the three types of applications, the healthcare segment is estimated to gain the largest market share of about 35% in the year 2037. The growth of the segment can be accredited to the presence of large number of patients in the healthcare industry, which is expanding notably. The hospitals in the healthcare sector are also growing rapidly in number. For instance, by the year 2022 there was noted to be approximately 6,100 hospitals in the United States. Hospitals provide a wide range of medical care. Physicians, called hospital doctors, typically specialize in internal medicine, pediatrics, or general practice. They have the knowledge to solve common problems and the resources to solve more complex medical problems. Hospitals may also offer specialized care, such as neurology, obstetrics and gynecology, and oncology. By definition of a hospital, a county hospital is typically a primary medical facility in a region with numerous intensive care and mobile beds for patients requiring long-term care.

Host Cell (Insect Cells, Mammalian)

The global recombinant proteins market is also segmented and analyzed for demand and supply by host cell into insect cells, and mammalian. Amongst these two segments, the mammalian segment is expected to garner a significant share of around 60% in the year 2037. The growth of the segment can be accredited to the increasing demand for biologics. Biologics, including monoclonal antibodies and other complex proteins, are increasingly being used to treat a range of diseases, such as cancer and autoimmune disorders. The mammalian cell expression system is well-suited to produce these complex proteins, driving demand for the mammalian segment in the global recombinant protein market. The mammalian cell expression system is a commonly used platform for the production of recombinant proteins due to its ability to produce complex proteins with post-translational modifications similar to those found in human cells. Advances in technology, such as genetic engineering and cell line development, have improved the efficiency and productivity of the mammalian cell expression system, making it a more attractive platform for the production of recombinant proteins. The biopharmaceutical industry is growing rapidly, driven by the increasing demand for biologics. This growth is expected to continue, driving demand for the mammalian segment over the forecast period.

Our in-depth analysis of the global market includes the following segments: